Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant718 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02901301 | Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer | unknown | Phase 1 / Phase 2 | 41 | Yonsei UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04781413 | Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer | unknown | Phase 1 / Phase 2 | 38 | Ruijin HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT02952729 |
| Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 |
| completed |
| Phase 1 |
| 120 |
| Mersana TherapeuticsINDUSTRY |
| 1 |
| Feb 24, 2021 |
| clinicaltrials |
| NCT04764084 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | unknown | Phase 1 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02500199 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | unknown | Phase 1 | 50 | Hengrui Therapeutics, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01183559 | A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery | completed | Phase 1 | 9 | Fox Chase Cancer CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02572687 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | completed | Phase 1 | 85 | Eli Lilly and CompanyINDUSTRY | 8 | Jan 20, 2021 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT01602406 | Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer | completed | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT04567069 | Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment | unknown | Phase 1 / Phase 2 | 45 | The Second Hospital of Shandong UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT04139070 | Electrochemotherapy for Non-curable Gastric Cancer | unknown | Phase 1 | 8 | Zealand University HospitalOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | terminated | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03734926 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 90 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT02512237 | A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | terminated | Phase 1 | 9 | Zhejiang Medicine Co., Ltd.INDUSTRY | 2 | Jun 5, 2020 | clinicaltrials |
| NCT04410887 | Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) | unknown | Phase 1 / Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Jun 1, 2020 | clinicaltrials |
| NCT01643499 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | completed | Phase 1 | 79 | University of ChicagoOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT03606928 | mFLOT Chemotherapy as First-line Treatment in GC | completed | Phase 1 / Phase 2 | 18 | Ruijin HospitalOTHER | 1 | Mar 20, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | withdrawn | Phase 1 | 0 | Lynkcell Inc.OTHER | 0 | Mar 11, 2020 | clinicaltrials |
| NCT02946671 | Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients | completed | Phase 1 | 16 | Osaka UniversityOTHER | 1 | Mar 6, 2020 | clinicaltrials |
| NCT04286711 | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 52 | China Medical University, ChinaOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT03425773 | Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care(BVAC-B) | completed | Phase 1 | 8 | Cellid Co., Ltd.INDUSTRY | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02415023 | A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 34 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02563548 | A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors | completed | Phase 1 | 56 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00446290 | Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer | completed | Phase 1 | 22 | Asan Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00565370 | Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP | completed | Phase 1 / Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01045538 | Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP | completed | Phase 1 / Phase 2 | 45 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01049620 | RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX | completed | Phase 1 | 40 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03086291 | A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy | unknown | Phase 1 | 9 | Samsung Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04182724 | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 57 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02276300 | HER2-Peptide Vaccination of Patients With Solid Tumors(HER2) | completed | Phase 1 | 2 | Technical University of MunichOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT02585908 | Safety and Efficacy of γδ T Cell Against Gastric Cancer | unknown | Phase 1 / Phase 2 | 120 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02406170 | Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma(REPEAT) | completed | Phase 1 / Phase 2 | 47 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02574663 | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | completed | Phase 1 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT04107142 | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | unknown | Phase 1 | 10 | CytoMed Therapeutics Pte LtdINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2021source: clinicaltrials